Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

HUNTSVILLE, June 17, 2025 (GLOBE NEWSWIRE) -- This press release has been updated to reflect the correct timing of the funding round.

Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform drug optimization technology, today congratulates its strategic partner and largest shareholder, Juvenescence Ltd., on the $76 million first tranche close of its targeted $150 million Series B financing, as well as its new strategic partnership with M42, a global tech-enables health company headquartered in Abu Dhabi.

“Juvenescence has been a critical partner to Serina, providing strategic guidance and capital that have helped us advance our POZ Platform into the clinic,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics. “We congratulate Richard and the entire Juvenescence team on this next phase of growth and look forward to working together to deliver breakthrough treatments to patients around the world.”

This significant investment and accompanying strategic alliance mark a major milestone in accelerating Juvenescence’s mission to develop innovative therapies targeting age-related diseases and extending healthspan. As part of this partnership, Juvenescence and M42 will launch a drug development hub in Abu Dhabi, combining AI-enabled drug discovery with cutting-edge data and clinical infrastructure to speed the development of novel therapeutics.

“We are grateful for the continued support of our investors, including new investor and strategic partner M42, who have joined us on this remarkable journey. Our partnership with M42 signifies a shared commitment to developing sustainable, long-term collaborations,” said Dr. Richard Marshall CBE, CEO of Juvenescence. “Together, we are excited about the opportunity to help build a leading life-sciences hub in Abu Dhabi and establish a pipeline of innovative therapeutics that will improve the lives of millions of patients.”

As a core portfolio company of Juvenescence, Serina is proud to be part of a growing network of science-driven enterprises working to transform the future of medicine.

About Serina Therapeutics

Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platformprovides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics, and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.